The molecular basis of pharmacological chaperoning in human α-galactosidase

Chemistry and Biology

Volumn 18, Issue 12, 2011, Pages 1521-1526

  Guce, Abigail I ^a   Clark, Nathaniel E ^a   Rogich, Jerome J ^a   Garman, Scott C ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1-DEOXYGALACTONOJIRIMYCIN; ALPHA GALACTOSIDASE; DRUG DERIVATIVE; GALACTOSE; MIGALASTAT;

ARTICLE; BINDING SITE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; FABRY DISEASE; GENETICS; HUMAN; METABOLISM; PH; PHASE TRANSITION; PROTEIN TERTIARY STRUCTURE; PROTEIN UNFOLDING; SITE DIRECTED MUTAGENESIS; TRANSITION TEMPERATURE; X RAY CRYSTALLOGRAPHY;

1-DEOXYNOJIRIMYCIN; ALPHA-GALACTOSIDASE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FABRY DISEASE; GALACTOSE; HUMANS; HYDROGEN-ION CONCENTRATION; MUTAGENESIS, SITE-DIRECTED; PHASE TRANSITION; PROTEIN STRUCTURE, TERTIARY; PROTEIN UNFOLDING; TRANSITION TEMPERATURE;

EID: 84555202420     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2011.10.012     Document Type: Article

References (29)

1. N. Asano, S. Ishii, H. Kizu, K. Ikeda, K. Yasuda, A. Kato, O.R. Martin, and J.Q. Fan In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1- deoxygalactonojirimycin and its derivatives Eur. J. Biochem. 267 2000 4179 4186 (Pubitemid 30436114)
2. E. Beutler Lysosomal storage diseases: natural history and ethical and economic aspects Mol. Genet. Metab. 88 2006 208 215 (Pubitemid 43963435)
3. R.O. Brady, A.E. Gal, R.M. Bradley, E. Martensson, A.L. Warshaw, and L. Laster Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency N. Engl. J. Med. 276 1967 1163 1167
4. F.E. Cohen, and J.W. Kelly Therapeutic approaches to protein-misfolding diseases Nature 426 2003 905 909 (Pubitemid 38056884)
5. R.J. Desnick, Y.A. Ioannou, and C.M. Eng Galactosidase A deficiency: Fabry disease C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic and Molecular Bases of Inherited Disease 2001 McGraw-Hill New York 3733 3774
6. C.M. Eng, and R.J. Desnick Molecular basis of Fabry disease: mutations and polymorphisms in the human α-galactosidase A gene Hum. Mutat. 3 1994 103 111 (Pubitemid 24077226)
7. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, L. Caplan, G.E. Linthorst, R.J. Desnick International Collaborative Fabry Disease Study Group Safety and efficacy of recombinant human α-galactosidase A - replacement therapy in Fabry's disease N. Engl. J. Med. 345 2001 9 16 (Pubitemid 32634266)
8. J.Q. Fan A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity Trends Pharmacol. Sci. 24 2003 355 360
9. J.Q. Fan A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity Biol. Chem. 389 2008 1 11
10. J.Q. Fan, and S. Ishii Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors FEBS J. 274 2007 4962 4971 (Pubitemid 47481192)
11. J.Q. Fan, S. Ishii, N. Asano, and Y. Suzuki Inhibitors enhance lysosomal α-galactosidase A activity in Fabry lymphoblasts: a possible molecular therapy for a genetic disorder Glycobiology 8 1998 1143-1143
12. J.Q. Fan, S. Ishii, N. Asano, and Y. Suzuki Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nat. Med. 5 1999 112 115 (Pubitemid 29051008)
13. K. Fantur, D. Hofer, G. Schitter, A.J. Steiner, B.M. Pabst, T.M. Wrodnigg, A.E. Stütz, and E. Paschke DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts Mol. Genet. Metab. 100 2010 262 268
14. A. Frustaci, C. Chimenti, R. Ricci, L. Natale, M.A. Russo, M. Pieroni, C.M. Eng, and R.J. Desnick Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy N. Engl. J. Med. 345 2001 25 32 (Pubitemid 32634268)
15. S.C. Garman, and D.N. Garboczi Structural basis of Fabry disease Mol. Genet. Metab. 77 2002 3 11 (Pubitemid 35178509)
16. S.C. Garman, and D.N. Garboczi The molecular defect leading to Fabry disease: structure of human α-galactosidase J. Mol. Biol. 337 2004 319 335 (Pubitemid 38293402)
17. A.I. Guce, N.E. Clark, E.N. Salgado, D.R. Ivanen, A.A. Kulminskaya, H. Brumer 3rd, and S.C. Garman Catalytic mechanism of human α-galactosidase J. Biol. Chem. 285 2010 3625 3632
18. H. Jo, K. Yugi, S. Ogawa, Y. Suzuki, and Y. Sakakibara Molecular basis of chemical chaperone effects of N-octyl-β-valienamine on human β-glucosidase in low/neutral pH conditions J Proteomics Bioinform 3 2010 104 112
19. G. Legler, and S. Pohl Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of α- and β-D-galactosidases Carbohydr. Res. 155 1986 119 129
20. R.L. Lieberman, J.A. D'aquino, D. Ringe, and G.A. Petsko Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 48 2009 4816 4827
21. T. Okumiya, S. Ishii, R. Kase, S. Kamei, H. Sakuraba, and Y. Suzuki α-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins Hum. Genet. 95 1995 557 561
22. G. Parenti Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics EMBO Mol Med 1 2009 268 279
23. G. Romeo, M. D'Urso, A. Pisacane, E. Blum, A. De Falco, and A. Ruffilli Residual activity of α-galactosidase A in Fabry's disease Biochem. Genet. 13 1975 615 628
24. A.R. Sawkar, S.L. Adamski-Werner, W.C. Cheng, C.H. Wong, E. Beutler, K.P. Zimmer, and J.W. Kelly Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles Chem. Biol. 12 2005 1235 1244 (Pubitemid 41628259)
25. R. Schiffmann, J.B. Kopp, H.A. Austin 3rd, S. Sabnis, D.F. Moore, T. Weibel, J.E. Balow, and R.O. Brady Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2001 2743 2749 (Pubitemid 32525371)
26. Y. Suzuki, S. Ogawa, and Y. Sakakibara Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities Perspect Medicin Chem 3 2009 7 19
27. A. Tan, L. van den Broek, S. van Boeckel, H. Ploegh, and J. Bolscher Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships J. Biol. Chem. 266 1991 14504 14510 (Pubitemid 21907532)
28. G.H. Yam, C. Zuber, and J. Roth A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder FASEB J. 19 2005 12 18 (Pubitemid 40069915)
29. G.H. Yam, N. Bosshard, C. Zuber, B. Steinmann, and J. Roth Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants Am. J. Physiol. Cell Physiol. 290 2006 C1076 C1082